Vogenx Inc.(VOGX)

Biotechnology · Raleigh, NC

$16.25-0.90 (-5.26%)

Delayed quote: Oct 6, 2026, 3:55 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T19:59:35.728Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:59:35.728Z.

Quote observation: 2026-10-06T19:55:08.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 225,938,887
Total debt: N/A
Cash: N/A
TTM operating EBITDA: N/A

FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

VOGX EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

VOGX Competitors' EV/EBITDA Ratio

VOGX

Vogenx Inc.

Current

Market Cap

$225.94M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAUT

Nautilus Biotechnolgy, Inc.

vs VOGX

Market Cap

$225.24M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BDSX

Biodesix, Inc.

vs VOGX

Market Cap

$227.60M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PROF

Profound Medical Corp.

vs VOGX

Market Cap

$220.93M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IFRX

InflaRx N.V.

vs VOGX

Market Cap

$232.72M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GLSI

Greenwich LifeSciences, Inc.

vs VOGX

Market Cap

$231.77M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MGNX

MacroGenics, Inc.

vs VOGX

Market Cap

$231.37M

EV/EBITDA Ratio

N/A

TTM Avg

133.55x

3Y Avg

183129.66x

5Y Avg

183129.66x

KROS

Keros Therapeutics, Inc.

vs VOGX

Market Cap

$218.30M

EV/EBITDA Ratio

N/A

TTM Avg

1.40x

3Y Avg

1.40x

5Y Avg

1.40x

SIGA

SIGA Technologies, Inc.

vs VOGX

Market Cap

$235.97M

EV/EBITDA Ratio

N/A

TTM Avg

5.07x

3Y Avg

4.97x

5Y Avg

6.62x

UTMD

Utah Medical Products, Inc.

vs VOGX

Market Cap

$235.30M

EV/EBITDA Ratio

18.56x

TTM Avg

9.66x

3Y Avg

8.05x

5Y Avg

8.98x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Vogenx Inc. (VOGX)	$225.94M	N/A	N/A	N/A	N/A
Nautilus Biotechnolgy, Inc. (NAUT)vs ›	$225.24M	N/A	N/A	N/A	N/A
Biodesix, Inc. (BDSX)vs ›	$227.60M	N/A	N/A	N/A	N/A
Profound Medical Corp. (PROF)vs ›	$220.93M	N/A	N/A	N/A	N/A
InflaRx N.V. (IFRX)vs ›	$232.72M	N/A	N/A	N/A	N/A
Greenwich LifeSciences, Inc. (GLSI)vs ›	$231.77M	N/A	N/A	N/A	N/A
MacroGenics, Inc. (MGNX)vs ›	$231.37M	N/A	133.55x	183129.66x	183129.66x
Keros Therapeutics, Inc. (KROS)vs ›	$218.30M	N/A	1.40x	1.40x	1.40x
SIGA Technologies, Inc. (SIGA)vs ›	$235.97M	N/A	5.07x	4.97x	6.62x
Utah Medical Products, Inc. (UTMD)vs ›	$235.30M	18.56x	9.66x	8.05x	8.98x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics